September 10, 2025Blood AdvancesOpen Access

Immunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemia

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective analysis explores infection rates and mortality in patients with chronic lymphocytic leukemia receiving immunoglobulin therapy.

Patients with chronic lymphocytic leukemia experienced doubled serious infections despite immunoglobulin replacement therapy.
Over a 14-year study period, 12.1% of patients received immunoglobulin therapy, correlating with higher infection rates during treatment.
Kaplan-Meier survival analysis revealed a significant connection between serious infections and increased mortality in chronic lymphocytic leukemia.
Further research is warranted to establish causality between immunoglobulin therapy and infection outcomes in this population.

Albornoz et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis explores infection rates and mortality in patients with chronic lymphocytic leukemia receiving immunoglobulin therapy.